An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
01 Oct 2022
Historique:
pubmed: 8 3 2022
medline: 5 10 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

Nivolumab is an immune-checkpoint inhibitor (ICI) that can induce unique treatment-related toxicities, such as immune-related adverse events (irAEs). Myocarditis is a serious irAE with an incidence between 0.06% and 1.14%. Although the peak onset of irAE is generally within three months from the start of treatment, we experienced an autopsy case of late-onset fulminant myocarditis caused by nivolumab in Epstein Barr virus-associated gastric cancer. Pathological complete remission of the primary lesion was confirmed by the autopsy. We should consider possible complications of cardiac irAEs, especially fulminant myocarditis, even beyond three months after starting ICI therapy.

Identifiants

pubmed: 35249925
doi: 10.2169/internalmedicine.9161-21
pmc: PMC9593165
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
Immune Checkpoint Inhibitors 0
Nivolumab 31YO63LBSN

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2867-2871

Références

J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
BMC Cancer. 2019 Oct 21;19(1):974
pubmed: 31638948
Gan To Kagaku Ryoho. 2020 Apr;47(4):725-727
pubmed: 32389997
Circulation. 2020 Jun 16;141(24):2031-2034
pubmed: 32539614
Circulation. 2007 Oct 30;116(18):2062-71
pubmed: 17938288
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31988143
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
JAMA Oncol. 2018 Mar 01;4(3):374-378
pubmed: 28975219
Lab Invest. 1996 Jul;75(1):67-76
pubmed: 8683941
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Int J Oncol. 2015 Apr;46(4):1421-34
pubmed: 25633561
Gastric Cancer. 2020 May;23(3):510-519
pubmed: 31863227
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Front Cardiovasc Med. 2019 Jan 23;6:3
pubmed: 30729114
Cardiovasc Res. 2019 Apr 15;115(5):854-868
pubmed: 30715219
Can J Cardiol. 2018 Jun;34(6):812.e1-812.e3
pubmed: 29801747
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052

Auteurs

Ken Naganuma (K)

Department of Medical Oncology, Saitama Medical University International Medical Center, Japan.

Yosuke Horita (Y)

Department of Medical Oncology, Saitama Medical University International Medical Center, Japan.

Keisuke Matsuo (K)

Department of Cardiology, Saitama Medical University International Medical Center, Japan.

Yu Miyama (Y)

Department of Pathology, Saitama Medical University International Medical Center, Japan.

Yoshiaki Mihara (Y)

Department of Medical Oncology, Saitama Medical University International Medical Center, Japan.

Masanori Yasuda (M)

Department of Pathology, Saitama Medical University International Medical Center, Japan.

Shintaro Nakano (S)

Department of Cardiology, Saitama Medical University International Medical Center, Japan.

Tetsuya Hamaguchi (T)

Department of Medical Oncology, Saitama Medical University International Medical Center, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH